NCT00792948 2026-03-18
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
132 trialsNCT02143414 2026-03-18
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03419234 2026-03-12
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04438382 2026-02-27
Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT01314118 2026-02-24
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Janssen Biotech, Inc.
Phase 2 Completed
NCT04569032 2026-02-18
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen Inc.
Phase 2 Completed
NCT03943901 2026-01-29
Split-Dose R-CHOP for Older Adults With DLBCL
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT03338790 2026-01-27
CheckMate 9KD
Bristol-Myers Squibb
Phase 2 Completed
NCT03565835 2026-01-26
Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer
Montefiore Medical Center
Phase 2 Completed
NCT01995058 2026-01-08
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
Exelixis
Phase 2 Terminated
NCT00006436 2025-12-30
EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03431350 2025-12-23
QUEST
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT02985957 2025-12-22
CheckMate 650
Bristol-Myers Squibb
Phase 2 Completed
NCT03007732 2025-12-05
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
University of California, San Francisco
Phase 2 Completed
NCT03113500 2025-11-14
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT00136435 2025-10-20
A Study in Adults With Untreated Acute Lymphoblastic Leukemia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03098836 2025-09-12
PANTHER
Duke University
Phase 2 Completed
NCT00001337 2025-06-22
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00001379 2025-06-19
Treatment and Natural History Study of Lymphomatoid Granulomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02903368 2025-06-13
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01375140 2025-06-08
Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02420717 2025-06-08
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03384654 2025-05-25
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Janssen Research & Development, LLC
Phase 2 Completed
NCT03412565 2025-04-29
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Janssen Research & Development, LLC
Phase 2 Completed
NCT02496585 2025-04-16
Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01309672 2025-02-26
S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
SWOG Cancer Research Network
Phase 2 Completed
NCT00390793 2025-02-17
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01650194 2024-12-10
A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
Astellas Pharma Inc
Phase 2 Completed
NCT02218606 2024-12-10
Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03414034 2024-11-07
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
Cardiff Oncology
Phase 2 Completed
NCT03488225 2024-07-16
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02199184 2024-06-11
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02903160 2024-02-07
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT01972217 2023-11-14
Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.
AstraZeneca
Phase 2 Completed
NCT00734149 2023-11-07
MVP
Duke University
Phase 2 Completed
NCT03649841 2023-10-26
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
University of Washington
Phase 2 Terminated
NCT04660799 2023-10-12
A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
Phase 2 Completed
NCT00574496 2023-09-28
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00352027 2023-09-22
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT01336933 2023-09-22
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
University of Nebraska
Phase 2 Completed
NCT00039130 2023-08-21
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00003910 2023-07-05
Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT00274924 2023-06-29
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01390584 2023-06-29
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT01092182 2023-04-27
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00005780 2023-01-31
Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01746173 2023-01-30
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01775475 2022-10-10
Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma
AIDS Malignancy Consortium
Phase 2 Completed
NCT01030900 2022-10-06
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02531308 2022-09-28
DLBCL
Rush University Medical Center
Phase 2 Terminated